Clinical trial
A Study of Trabectedin in Patients With Advanced Ovarian Cancer
NCT00050414 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00050414 |
|---|---|
| Title | A Study of Trabectedin in Patients With Advanced Ovarian Cancer |
| Official title | Phase 2 Study of Efficacy and Safety of Trabectedin in Subjects With Advanced Ovarian Cancer |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | PharmaMar Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female |
| Intervention type | Drug |
| Interventions | Trabectedin, Dexamethasone |
| Enrollment | 147 |
| Start date | Oct 1, 2002 |
| Completion | Sep 1, 2005 |
| First posted | Dec 10, 2002 |
| Last update posted | Jan 10, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: